Table of Content

Table of Contents

1          Executive Summary

2          Introduction & Overview

3          Background

4          Technology Profiles

4.1       Overview & Discussion
4.1.1    Intracellular Target Discovery
4.1.2    TCR Discovery Technologies
4.1.3    Generation of TCR-like Antibodies
4.1.4    Generation of TCR Fusion Proteins against Intracellular Targets
4.1.5    Generation of Cell Penetrating Biologics against Intracellular Targets

4.2       Technologies for Discovery of Intracellular Targets
4.2.1    XPRESIDENT
4.2.2    Targets for TCRs (Immunocore)
4.2.3    Phosphopeptide Library
4.2.4    HTS Platform for Neoantigen Identification
4.2.5    ECLIPSE Platform
4.2.6    EpiTarget Platform
4.2.7    Soluble HLA (sHLA) Molecules
4.2.8    Phagemers & SSIp display
4.2.9    Peptide/MHC Complexes
4.2.10  TCR Target Discovery

4.3       Technologies for Discovery of TCRs
4.3.1    Naturally Selected TCRs
4.3.2    TCRs by ImmTAC Technology
4.3.3    HTS for TUMAP-Restricted TCRs
4.3.4    Natural TCR Library
4.3.5    Sleeping-Beauty Expression System
4.3.6    TCR-GENerator
4.3.7    T-Rx Mammalian TCR Display
4.3.8    Single Cell Sequencing Platform
4.3.9    Immune Repertoire Capture
4.3.10  Combinatorial TCR Exchange (CTE)
4.3.11  VelociT for T-Cell Receptor Discovery

4.4       Technologies for Generation of TCRL Antibodies
4.4.1    TandAb
4.4.2    BiTE
4.4.3    E-Alpha Phage Display
4.4.4    HuTARG Protein Engineering
4.4.5    MAR & TriTE
4.4.6    TCRL Antibodies
4.4.7    TCRm Antibodies
4.4.8    Ylanthia Fab library
4.4.9    TCRL ADCs

4.5       Technologies for Generation of TCR Fusion Proteins
4.5.1    ImmTAC
4.5.2    TCR Bispecifics
4.5.3    STAR

4.6       Technologies for Generation of Cell Penetrating Biologics
4.6.1    Cell-Penetrating alpha Bodies
4.6.2    Anti-DNA Autoantibodies
4.6.3    Cell Penetrating Mini Proteins (CPMP)
4.6.4    Feldan Shuttle
4.6.5    Shark VNARs
4.6.6    iMab
4.6.7    iTABs
4.6.8    Stapled Peptides
4.6.9    Single Domain Antibodies

5          Pipeline Analysis and Product Profiles

5.1       Overview Product Profiles and Pipeline Discussion

5.2       Profiles of Selected TCRL Antibodies & TCR Fusion Proteins
5.2.1    IMCgp100
5.2.2    ALT-801
5.2.3    H8F4
5.2.4    MMP1-003 TandAb
5.2.5    ESK1 & ESKM
5.2.6    RL1B

5.3       Profiles of Selected Cell Penetrating Peptides, Proteins & Antibodies
5.3.1    ALRN-6924
5.3.2    Anti-Mcl-1 CPAB
5.3.3    PAT-DX1 & Other Deoxymabs
5.3.4    RT11-i
5.3.5    SBT-100

6          Stakeholder Analysis & Company Profiles

6.1       Stakeholder Analysis and Overview of Company Profiles

6.2       Profiles of Companies with Target Discovery and TCR Fusion Protein Technologies
6.2.1    Agenus
6.2.2    Atreca
6.2.3    Immatics Biotechnologies
6.2.4    Immunocore
6.2.5    Regeneron Pharmaceuticals

6.3       Profiles of Companies with Target Discovery and TCR-Like Antibody Technologies
6.3.1    AbeXXa
6.3.2    Adicet Bio
6.3.3    MD Anderson Cancer Center
6.3.4    Pure MHC

6.4       Profiles of Companies with TCR Fusion Protein and/or TCRL Antibody Technologies
6.4.1    Affimed Therapeutics
6.4.2    NantCell (Altor Bioscience)
6.4.3    Eureka Therapeutics
6.4.4    Innovative Targeting Solutions (ITS)
6.4.5    Morphosys
6.4.6    Receptor Logic (now Pure MHC)
6.4.7    Timmune Biotech

6.5       Profiles of Companies with TCR Discovery Technologies only used for T-Cell Therapy
6.5.1    BioNTech
6.5.2    Gadeta
6.5.3    Gilead Sciences (Kite Pharma)
6.5.4    Juno Therapeutics
6.5.5    Medigene
6.5.6    ZIOPHARM Oncology

6.6       Profiles of Companies with Cell Penetrating (CP) Peptide, Protein or Antibody Technologies
6.6.1    Aileron Therapeutics
6.6.2    Complix
6.6.3    Elasmogen
6.6.4    Feldan Therapeutics
6.6.5    Fog Pharmaceuticals
6.6.6    Orum Pharmaceuticals
6.6.7    Patrys
6.6.8    Singh Biotechnology
6.6.9    Sorrento Therapeutics & LA Cell

6.7       Profiles of Big Pharma & Biotech Companies Active in the Intracellular Target and TCR & Cell Penetrating Biologics Field
6.7.1    AbbVie
6.7.2    Amgen
6.7.3    Astellas Pharma
6.7.4    AstraZeneca
6.7.5    Boehringer Ingelheim
6.7.6    Eli Lilly
6.7.7    GlaxoSmith-Kline
6.7.8    Janssen Biotech
6.7.9    Merck
6.7.10  Novartis
6.7.11  Roche

6.8       Profiles of Other Companies with Stakes in the Field of Intracellular Targets and TCR & Cell Penetrating Biologics
6.8.1    Nextera
6.8.2    Xencor
6.8.3    Zymeworks

7          Deals & Financing
7.1       Partnering Deals between Big Pharma and Technology Companies
7.2       Acquisitions of Technology Companies
7.3       Collaboration and Licensing Deals between Technology Companies
7.4       Financing Sources of Technology Companies

8          Trends & Outlook

10        References

Tables in the report
  • Overview of Corporate Technologies to Discover Intracellular Targets for TCRs
  • Overview of Corporate Technologies to Discover Therapeutic TCRs
  • Overview of Technologies for Generation of TCRL Antibodies against Intracellular Targets
  • Overview of Technologies for Generation of TCR Fusion Proteins against Intracellular Targets
  • Overview of Technologies for Generation of Cell Penetrating Biologics against Intracellular Targets
  • Affinity Enhancement of TCRs by Immunocore technology
  • Examples of Direct Identification and Confirmation of Class I MHC-Peptide Epitopes on Cells with T-Cell Receptor Mimic Antibodies
  • Profiles of Selected TCRL Antibodies & TCR Fusion Proteins
  • Profiles of Selected Cell Penetrating Peptides, Proteins & Antibodies
  • Clinical Studies with IMCgp100
  • Profiles of Companies with Target Discovery and TCR Fusion Protein Technologies
  • Profiles of Companies with Target Discovery and TCR-Like Antibody Technologies
  • Profiles of Companies with TCR Fusion Protein and/or TCRL Antibody Technologies
  • Profiles of Companies with TCR Discovery Technologies only used for T-Cell Therapy
  • Profiles of Companies with Cell Penetrating (CP) Peptide, Protein or Antibody Technologies
  • Profiles of Big Pharma & Biotech Companies Active in the Intracellular Target and TCR & Cell Penetrating Biologics Field
  • Profiles of Other Companies with Stakes in the Field of Intracellular Targets and TCR & Cell Penetrating Biologics
  • Antibody-based immunotherapeutics against pMHCs* discovered by immatics’ XPRESIDENT technology
  • Immunocore’s Proprietary and Partnered Pipeline of TCR Fusion Proteins
  • Goals and Terms of Immunocore’s Partnering Deals for ImmTAC Technology
  • Innovative Targeting Solutions and Drug Candidates from HuTARG Platform
  • Examples of Direct Identification and Confirmation of Class I MHC-Peptide Epitopes on Cells with T-Cell Receptor Mimic Antibodies
  • Pipeline sdAbs from Singh Biotechnology
  • Collaboration and Licensing Agreements between Big Pharma/Biotech and Technology Companies for Intracellular Targets and Therapeutic Biologics
  • Acquisition of Technology Companies in the Field
  • Collaboration and Licensing Agreements between Technology Companies
  • Financing Sources of Technology Companies in the Field